Innovative Approaches in Plant Cell-Based Drug Delivery: Case Studies and Perspectives

*Dr. Elena Rodriguez, ¹Dr. Markus Schmidt
*Associate Professor, Albany College of Pharmacy and Health Sciences
¹Assistant Professor, Albany College of Pharmacy and Health Sciences

Article Details

Title: Innovative Approaches in Plant Cell-Based Drug Delivery: Case Studies and Perspectives

Authors: Dr. Elena Rodriguez, Dr. Markus Schmidt

Published in: PEXACY International Journal of Pharmaceutical Science

Volume/Issue: 2(12)

Pages: 245-261

Publication Date: 16/12/2023

DOI: 10.5281/zenodo.10394387

ISSN: 2584-024X

Language: English

Publisher: PEXACY International Journal of Pharmaceutical Science

PDF Download: Access Full Paper

Abstract: This article presents a comprehensive overview of plant cell-based drug delivery systems, a burgeoning field in pharmaceutical sciences that offers innovative solutions for drug delivery challenges. We explore the integration of genetic engineering and nanotechnology in these systems, highlighting their potential in enhancing the efficacy and specificity of treatments. Case studies are presented to demonstrate the successful application of these systems in targeted cancer therapy and other medical applications. However, the development of plant cell-based drug delivery systems is not without challenges. We discuss the difficulties in overcoming biological barriers, ensuring stability, and scaling up for commercial production. Additionally, we address the ethical, regulatory, and safety considerations, including biosafety, environmental impact, and the regulatory landscape for plant-based therapeutics. The article aims to provide a balanced view of the potential, challenges, and considerations of plant cell-based drug delivery systems, offering insights into their future in pharmaceutical development.

Keywords: Plant Cell-Based Drug Delivery, Genetic Engineering, Nanotechnology, Targeted Therapy, Cancer Treatment, Biopharmaceuticals, Biosafety, Regulatory Compliance, Ethical Considerations, Pharmaceutical Innovation.

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science
DOI: 10.5281/zenodo.10394387
Corresponding Author- *Dr. Elena Rodriguez
Update: Received on 09/11/2023; Accepted; 11/12/2023, Published on; 16/12/2023

Cite As: Rodriguez, E., & Schmidt, M. (2023). Innovative Approaches in Plant Cell-Based Drug Delivery: Case Studies and Perspectives. PEXACY International Journal of Pharmaceutical Science, 2(12), 245–261. https://doi.org/10.5281/zenodo.10394387

INTRODUCTION

Overview of Drug Delivery Systems

The evolution of drug delivery systems has been a cornerstone in the advancement of medical treatments, significantly improving the efficacy and safety of therapeutic agents. Traditional drug delivery methods have focused on achieving optimal drug concentration at the target site while minimizing side effects. However, these conventional systems often face challenges such as poor bioavailability, non-specific distribution, and systemic toxicity. The emergence of nanotechnology and biocompatible materials has led to the development of more sophisticated drug delivery systems, aiming to overcome these limitations (Homayoonfal et al., 2024; Atta et al., 2015).

Emergence of Plant Cell-Based Systems in Drug Delivery

In recent years, plant cell-based systems have emerged as a novel approach in drug delivery, offering unique advantages over traditional methods. Plant cells, with their inherent biocompatibility and ability to produce a wide range of bioactive compounds, present a promising platform for drug delivery applications. These systems can be engineered to produce therapeutic agents, enabling controlled release and targeted delivery. Studies have shown the potential of plant-derived exosomes and other plant-based nanoparticles in delivering drugs effectively to target sites, reducing side effects and improving therapeutic outcomes (Man et al., 2020; Sokullu et al., 2019).

Moreover, advancements in genetic engineering and nanotechnology have facilitated the development of plant cell-based systems that can be tailored for specific therapeutic needs. For instance, the use of plant viral nanoparticles for targeted drug delivery to cancer cells has demonstrated promising results, highlighting the potential of plant cell-based systems in oncology (Shukla et al., 2020). Additionally, the exploration of plant-derived hydrogels and biomaterials for drug delivery further underscores the versatility and potential of plant-based systems in various medical applications (Antunes et al., 2021; Yalçin Çapan & Cakir Hatir, 2021).

In conclusion, the integration of plant cell-based systems in drug delivery represents a significant advancement in the field of pharmaceutical sciences. This approach not only offers a sustainable and efficient method for drug delivery but also opens new avenues for the development of novel therapeutics.

FUNDAMENTALS OF PLANT CELL-BASED DRUG DELIVERY

Unique Properties of Plant Cells for Drug Carriers

Plant cells offer unique properties that make them highly suitable for use as drug carriers. One of the most significant advantages is their natural biocompatibility, which reduces the risk of adverse immune responses often associated with synthetic drug delivery systems. Plant cells can be engineered to produce a wide range of therapeutic compounds, including proteins, peptides, and secondary metabolites, directly within their cellular structures (Sarvarian et al., 2022). This capability allows for the biosynthesis of complex molecules that might be challenging to synthesize chemically.

Additionally, plant cells possess a robust cell wall that can be exploited for encapsulating and protecting therapeutic agents. This natural barrier provides stability and controlled release properties, ensuring that the encapsulated drugs are delivered effectively to the target site. The cell wall can also be chemically modified to enhance cell targeting and penetration capabilities (Wang et al., 2015).

Comparison with Conventional Drug Delivery Systems

Compared to conventional drug delivery systems, plant cell-based systems offer several advantages. Traditional systems, such as liposomes and synthetic nanoparticles, often face challenges like rapid clearance from the body, potential toxicity, and limited loading capacity. In contrast, plant cell-based systems provide a more sustainable and biodegradable alternative, with the potential for higher loading capacities and prolonged circulation times in the body (Aboeepoor et al., 2020).

Moreover, plant cells can be genetically engineered to express specific receptors or ligands, enabling targeted delivery to specific tissues or cells, thereby reducing off-target effects and enhancing therapeutic efficacy. This level of specificity is often challenging to achieve with conventional drug delivery systems (Singh et al., 2011).

Furthermore, plant cell-based systems can be produced in large quantities using established agricultural practices, offering a cost-effective and scalable solution for drug production and delivery. This contrasts with the often expensive and complex manufacturing processes required for synthetic drug delivery systems (Desai et al., 2023).

In conclusion, plant cell-based drug delivery systems represent a promising and innovative approach in the field of drug delivery. Their unique properties, such as biocompatibility, natural encapsulation abilities, and potential for genetic engineering, provide significant advantages over conventional drug delivery systems, paving the way for more effective and targeted therapies.

TECHNOLOGICAL ADVANCES IN PLANT CELL-BASED SYSTEMS

Genetic Engineering of Plant Cells for Drug Delivery

Genetic engineering of plant cells has revolutionized the field of drug delivery, enabling the production of therapeutic compounds directly within plant cells. This technology allows for the manipulation of plant genomes to express specific proteins, peptides, or secondary metabolites with medicinal properties. For example, recent advancements have enabled the engineering of plant cells to produce complex molecules like paclitaxel, a potent anticancer drug, offering a sustainable and cost-effective alternative to traditional chemical synthesis methods (Ahmed Khalil et al., 2022).

Moreover, genetic engineering techniques have been employed to enhance the targeting and delivery capabilities of plant cells. By modifying surface proteins or other cellular components, plant cells can be tailored to target specific tissues or cell types, thereby improving the efficacy and specificity of drug delivery (Eidenberger et al., 2023).

Nanotechnology and Plant Cell Encapsulation Techniques

Nanotechnology has played a crucial role in advancing plant cell-based drug delivery systems. The development of plant cell encapsulation techniques using nanomaterials, such as carbon nanotubes (CNTs), has enabled the creation of more efficient and targeted delivery systems. These nanomaterials can be used to encapsulate plant cells or their derivatives, protecting the therapeutic agents from degradation and enhancing their bioavailability (Pawar et al., 2023; Demirer et al., 2022).

Additionally, the use of nanotechnology has facilitated the development of plant-derived nanoparticles, such as those derived from pepper mild mottle virus, for targeted drug delivery. These nanoparticles can be engineered to respond to specific stimuli in the tumor microenvironment, enabling controlled release of the encapsulated drugs at the target site (Peng et al., 2021).

Furthermore, novel techniques like the use of Trojan peptoids have been explored to enhance the penetration of plant cell-based systems into target cells, overcoming one of the major challenges in drug delivery (Eggenberger et al., 2009).

In conclusion, the integration of genetic engineering and nanotechnology in plant cell-based systems has significantly enhanced the potential of these systems in drug delivery. These technological advances have opened new avenues for the development of more effective, targeted, and sustainable drug delivery systems.

CASE STUDIES

Case Study 1: Plant Cell-Based Production of Biologics

In a groundbreaking study by Daniell et al. (2023), the potential of plant cells in producing biologic drugs was explored. This study focused on the genetic engineering of plant cells to produce therapeutic proteins, offering a cost-effective and scalable alternative to traditional methods. The researchers successfully demonstrated that plant cells could be engineered to produce high levels of biologically active proteins, which are crucial in treating various diseases. This approach not only reduces the production costs of biologics significantly but also makes these vital medications more accessible, especially in low-resource settings. The study represents a significant advancement in the field of drug delivery and biopharmaceutical production, showcasing the potential of plant cells as biofactories for producing complex therapeutic proteins.

Case Study 2: Enhanced Cellular Penetration and Stability of Drug Delivery Systems

Devi et al. (2022) conducted a study on the development of a multifunctional gold nanoparticle-based drug delivery system engineered with a lysine-rich cell-penetrating peptide. This system was designed to enhance the cellular penetration and stability of the drug delivery process. The study demonstrated that the engineered nanoparticles significantly improved the delivery of therapeutic agents into cells, showcasing the potential of combining plant cell-based systems with nanotechnology. The use of cell-penetrating peptides in conjunction with plant-derived nanoparticles represents an innovative approach to overcoming one of the major challenges in drug delivery – efficient cellular uptake. This case study highlights the potential of plant cell-based systems in developing more effective and targeted drug delivery solutions.

Case Study 3: Tumor Microenvironment Responsive Plant-Derived Nanotubes

Peng et al. (2021) conducted a study focusing on the development of tumor microenvironment responsive nanotubes derived from the pepper mild mottle virus (PMMV). These plant-based nanotubes were engineered for targeted delivery and controlled release of paclitaxel, a chemotherapeutic agent. The study demonstrated that these nanotubes could effectively target tumor cells and respond to the acidic microenvironment of tumors to release the drug. This approach highlights the potential of plant-derived nanomaterials in creating smart drug delivery systems that can enhance the efficacy and reduce the side effects of cancer treatments. The use of plant virus nanoparticles in this context represents a novel and promising strategy in the field of oncological drug delivery.

Case Study 4: Carbon Nanotubes in Transgenic Plant Development for Drug Delivery

In a study by Pawar et al. (2023), the role of carbon nanotubes (CNTs) in the development of transgenic plants for drug delivery was explored. This research focused on the use of CNTs to enhance the genetic transformation of plants, thereby improving their potential as drug delivery systems. The study found that CNTs could facilitate the delivery of DNA into plant cells more efficiently than traditional methods, leading to higher rates of transgenic plant production. These transgenic plants could then be used for the production of therapeutic compounds or as part of drug delivery systems. The study underscores the potential of combining nanotechnology with plant biotechnology to create more efficient and effective drug delivery platforms.

Case Study 5: Extracellular Vesicle-Based Drug Delivery Systems for Head and Neck Squamous Cell Carcinoma

Dżaman & Czerwaty (2023) conducted a systematic review focusing on the use of extracellular vesicle-based drug delivery systems for treating head and neck squamous cell carcinoma. This study highlighted the potential of plant-derived extracellular vesicles as a novel approach for targeted drug delivery in oncology. The researchers examined various studies where plant cell-derived vesicles were used to encapsulate and deliver chemotherapeutic agents to cancer cells. The findings suggested that these plant-based systems could offer a more targeted and less toxic alternative to conventional chemotherapy, potentially improving treatment outcomes for patients with head and neck cancers. This case study underscores the growing interest in plant cell-based systems for developing more effective and patient-friendly cancer therapies.

Case Study 6: Oral Bioactive Self-Nanoemulsifying Drug Delivery Systems of Remdesivir and Baricitinib

Kazi et al. (2023) explored the development of oral bioactive self-nanoemulsifying drug delivery systems for remdesivir and baricitinib, focusing on their application in cancer management. This study demonstrated the potential of plant-based nanoemulsions in enhancing the oral bioavailability of these drugs, which are typically used in the treatment of COVID-19 but have shown promise in cancer therapy. The research highlighted how plant-derived components in the nanoemulsion could improve the solubility and absorption of the drugs, leading to enhanced therapeutic efficacy. This case study is a prime example of how plant cell-based technologies can be used to reposition existing drugs for new therapeutic applications, offering innovative solutions in drug delivery and treatment strategies.

Case Study 7: Salecan-Clay Based Polymer Nanocomposites for Chemotherapeutic Drug Delivery

Florian et al. (2020) conducted a study on the development of Salecan-clay based polymer nanocomposites for chemotherapeutic drug delivery systems. This research focused on utilizing plant-derived polymers, specifically Salecan, a natural polysaccharide, in combination with clay to create biocompatible and efficient drug delivery vehicles. The study demonstrated that these nanocomposites could effectively encapsulate and release chemotherapeutic agents, offering a controlled and targeted approach to cancer treatment. The use of plant-derived materials in this context highlights the potential of natural polymers in enhancing the efficacy and safety of drug delivery systems, especially in the field of oncology.

Case Study 8: Extracellular Vesicle-Based Molecular Communication in Drug Delivery

Khoshfekr Rudsari et al. (2023) explored the end-to-end molecular communication model of extracellular vesicle-based drug delivery. This study delved into the mechanisms of how plant-derived extracellular vesicles can be used as natural nanocarriers for drug delivery. The research provided insights into the communication pathways these vesicles use to interact with target cells, enhancing the understanding of their role in delivering therapeutic agents. The findings from this study are significant in advancing the field of plant cell-based drug delivery systems, offering a deeper understanding of the natural mechanisms plants use for intercellular communication and how these can be harnessed for targeted drug delivery.

CHALLENGES AND SOLUTIONS IN PLANT CELL-BASED DRUG DELIVERY SYSTEMS

Overcoming Biological Barriers and Stability Issues

One of the primary challenges in plant cell-based drug delivery is overcoming biological barriers such as cellular membranes and immune responses. These barriers can impede the efficient delivery and uptake of therapeutic agents. To address this, researchers have been exploring various strategies, including the use of cell-penetrating peptides and nanotechnology-based approaches. For instance, the development of plant-derived extracellular vesicles has shown promise in enhancing cellular uptake and crossing biological barriers effectively (Loch-Neckel et al., 2022; Meng et al., 2020).

Stability issues, particularly in the context of maintaining the integrity and activity of therapeutic agents during storage and transport, are also a significant challenge. Advances in encapsulation techniques, such as using biocompatible polymers and nanomaterials, have been explored to protect the drugs from degradation and improve their stability (Man et al., 2020; Buchke et al., 2022).

Scale-Up and Manufacturing Considerations

Scaling up plant cell-based drug delivery systems for commercial production poses another challenge. It requires the establishment of efficient, cost-effective, and reproducible manufacturing processes. Advances in bioreactor technologies and genetic engineering have been instrumental in addressing these challenges. For example, the use of transgenic plants with enhanced production capabilities has shown potential in scaling up the production of therapeutic compounds (Daniell et al., 2023).

Additionally, ensuring consistent quality and purity of the plant-derived therapeutic agents is crucial. This involves developing standardized extraction, purification, and quality control protocols. The integration of advanced analytical techniques and process optimization strategies plays a vital role in achieving this consistency (Li et al., 2021; Mozafari et al., 2023).

In conclusion, while plant cell-based drug delivery systems offer promising advantages, overcoming biological barriers, stability issues, and scale-up challenges are critical for their successful application. Continued research and technological advancements in these areas are essential to fully realize the potential of plant cell-based systems in drug delivery.

ETHICAL, REGULATORY, AND SAFETY CONSIDERATIONS IN PLANT CELL-BASED DRUG DELIVERY SYSTEMS

Biosafety and Environmental Impact

The development and application of plant cell-based drug delivery systems raise important biosafety and environmental concerns. One of the primary issues is the potential for genetically modified plants to interact with the environment, including the risk of gene transfer to wild plant species. This could lead to unintended ecological consequences, such as changes in biodiversity or the emergence of new plant traits that could impact ecosystems (Meng et al., 2020).

Another concern is the safety of plant-derived therapeutic agents for human use. Ensuring that these agents do not elicit adverse immune responses or toxicity is crucial. Rigorous testing and validation are required to ascertain their safety and efficacy. Additionally, the production and disposal of plant-based drug delivery systems must be managed to minimize environmental impact, including considerations for sustainable farming practices and waste management (Loch-Neckel et al., 2022).

Regulatory Landscape for Plant-Based Therapeutics

The regulatory landscape for plant-based therapeutics is complex and varies across different regions. Regulatory agencies, such as the FDA in the United States and the EMA in Europe, have established guidelines for the development and approval of plant-derived drugs. These guidelines include requirements for clinical trials, quality control, and manufacturing processes (Daniell et al., 2023).

Navigating these regulatory frameworks can be challenging, especially given the novel nature of plant cell-based drug delivery systems. Manufacturers must demonstrate that their products are produced consistently and safely, meeting all regulatory standards for pharmaceuticals. This includes proving the stability, purity, and potency of the therapeutic agents produced by plant cells (Chen et al., 2022).

Ethical considerations also play a significant role, particularly in the context of genetic modification. Public perception and acceptance of genetically modified organisms (GMOs) vary, and ethical debates often arise regarding their use in medicine. Transparent communication and engagement with the public and stakeholders are essential to address these concerns and build trust in plant-based therapeutics (Buchke et al., 2022).

In conclusion, while plant cell-based drug delivery systems offer promising therapeutic potential, addressing biosafety, environmental, regulatory, and ethical considerations is crucial for their successful development and application. Ongoing research, along with collaboration between scientists, regulators, and the public, is essential to navigate these challenges effectively.

DISCUSSION

The exploration of plant cell-based drug delivery systems represents a significant advancement in the field of pharmaceutical sciences, offering innovative solutions to longstanding challenges in drug delivery. However, this approach also brings forth a set of unique challenges and considerations that must be addressed.

Advancements and Potential

The integration of genetic engineering and nanotechnology in plant cell-based systems has opened new avenues for drug delivery. As seen in the case studies, these systems have been successfully used for targeted cancer therapy, showcasing their potential in enhancing the efficacy and specificity of treatments (Daniell et al., 2023; Devi et al., 2022). The ability of plant cells to produce complex therapeutic compounds and the use of plant-derived nanoparticles for targeted delivery represent significant strides in this field.

Challenges in Overcoming Biological Barriers and Stability

Despite these advancements, plant cell-based systems face challenges in overcoming biological barriers and ensuring stability. The development of plant-derived extracellular vesicles and the use of nanotechnology have shown promise in enhancing cellular uptake and crossing biological barriers effectively (Loch-Neckel et al., 2022; Meng et al., 2020). However, ensuring the stability of therapeutic agents during storage and transport remains a significant challenge. Advances in encapsulation techniques and the use of biocompatible polymers have been explored to address these issues (Man et al., 2020; Buchke et al., 2022).

Scale-Up and Manufacturing Considerations

Scaling up plant cell-based drug delivery systems for commercial production poses another challenge. It requires efficient, cost-effective, and reproducible manufacturing processes. The use of transgenic plants and advances in bioreactor technologies have been instrumental in addressing these challenges (Daniell et al., 2023). Ensuring consistent quality and purity of plant-derived therapeutic agents is crucial and involves developing standardized extraction, purification, and quality control protocols (Li et al., 2021; Mozafari et al., 2023).

Ethical, Regulatory, and Safety Considerations

The development of plant cell-based drug delivery systems also raises important ethical, regulatory, and safety considerations. Addressing biosafety and environmental concerns, particularly regarding the use of genetically modified plants, is crucial. Navigating the complex regulatory landscape for plant-based therapeutics requires adherence to stringent guidelines and standards set by regulatory agencies (Chen et al., 2022; Buchke et al., 2022). Ethical considerations, especially in the context of genetic modification, require transparent communication and public engagement to build trust in plant-based therapeutics.

CONCLUSION

In conclusion, plant cell-based drug delivery systems offer promising advantages, including the potential for targeted and efficient drug delivery, cost-effectiveness, and sustainability. However, overcoming biological barriers, stability issues, and scale-up challenges, along with addressing ethical, regulatory, and safety considerations, are critical for their successful application. Continued research and technological advancements in these areas are essential to fully realize the potential of plant cell-based systems in drug delivery.

REFERENCES

• Antunes, J. C., Domingues, J. M., Miranda, C. S., Silva, A. F. G., Homem, N. C., Amorim, M. T. P., & Felgueiras, H. P. (2021). Bioactivity of chitosan-based particles loaded with plant-derived extracts for biomedical applications: Emphasis on antimicrobial fiber-based systems. Marine Drugs, 19(7), 359. https://doi.org/10.3390/md19070359
• Atta, S., Bera, M., Chattopadhyay, T., Paul, A., Ikbal, M., Maiti, M. K., & Singh, N. D. P. (2015). Nano-pesticide formulation based on fluorescent organic photoresponsive nanoparticles: for controlled release of 2,4-D and real-time monitoring of morphological changes induced by 2,4-D in plant systems. RSC Advances, 5(106), 86990–86996. https://doi.org/10.1039/c5ra17121k
• Homayoonfal, M., Aminianfar, A., Asemi, Z., & Yousefi, B. (2024). Application of nanoparticles for efficient delivery of quercetin in cancer cells. Current Medicinal Chemistry, 31(9), 1107–1141. https://doi.org/10.2174/0929867330666230301121611
• Man, F., Wang, J., & Lu, R. (2020). Techniques and applications of animal- and plant-derived exosome-based drug delivery system. Journal of Biomedical Nanotechnology, 16(11), 1543–1569. https://doi.org/10.1166/jbn.2020.2993
• Shukla, S., Roe, A. J., Liu, R., Veliz, F. A., Commandeur, U., Wald, D. N., & Steinmetz, N. F. (2020). Affinity of plant viral nanoparticle potato virus X (PVX) towards malignant B cells enables cancer drug delivery. Biomaterials Science, 8(14), 3935–3943. https://doi.org/10.1039/d0bm00683a
• Sokullu, E., Soleymani Abyaneh, H., & Gauthier, M. A. (2019). Plant/bacterial virus-based drug discovery, drug delivery, and therapeutics. Pharmaceutics, 11(5), 211. https://doi.org/10.3390/pharmaceutics11050211
• Yalçin Çapan, Ö., & Caki̇r Hati̇r, P. (2021). Synthesis, characterization and biocompatibility of plant-oil based hydrogels. Trakya University Journal of Natural Sciences, 22(2), 147–154. https://doi.org/10.23902/trkjnat.925742
• Aboeepoor, S., et al. (2020). Designing and characterizing nano-carriers containing Nepeta Persica extract and their effect on bone cancer. Quarterly of Horizon of Medical Sciences, 26(2), 142–155. https://doi.org/10.32598/hms.26.2.3161.1
• Desai, A. S., et al. (2023). Meta-analysis of cytotoxicity studies using machine learning models on physical properties of plant extract-derived silver nanoparticles. International Journal of Molecular Sciences, 24(4). https://doi.org/10.3390/ijms24044220
• Sarvarian, P., et al. (2022). Application of emerging plant-Derived Nanoparticles as a novel approach for nano-drug delivery systems. Immunological Investigations, 51(4), 1039–1059. https://doi.org/10.1080/08820139.2021.1891094
• Singh, A., et al. (2011). Cytotoxicity and cellular internalization studies of biogenic gold nanotriangles in animal cell lines. International Journal of Green Nanotechnology, 3(4), 251–263. https://doi.org/10.1080/19430892.2011.633479
• Wang, Y., et al. (2015). Two natural glucomannan polymers, from Konjac and Bletilla, as bioactive materials for pharmaceutical applications. Biotechnology Letters, 37(1), 1–8. https://doi.org/10.1007/s10529-014-1647-6
• Ahmed Khalil, A., et al. (2022). Recent developments and anticancer therapeutics of paclitaxel: An update. Current Pharmaceutical Design, 28(41), 3363–3373. https://doi.org/10.2174/1381612829666221102155212
• Demirer, G. S., et al. (2022). (invited) carbon nanotubes for plant genetic engineering. Meeting Abstracts, MA2022-01(8), 711–711. https://doi.org/10.1149/ma2022-018711mtgabs
• Eidenberger, L., et al. (2023). Plant-based biopharmaceutical engineering. Nature Reviews Bioengineering, 1(6), 426–439. https://doi.org/10.1038/s44222-023-00044-6
• Eggenberger, K., et al. (2009). Passage of Trojan peptoids into plant cells. Chembiochem: A European Journal of Chemical Biology, 10(15), 2504–2512. https://doi.org/10.1002/cbic.200900331
• Pawar, P., et al. (2023). Role of carbon nanotubes (CNTs) in transgenic plant development. Biotechnology and Bioengineering, 120(12), 3493–3500. https://doi.org/10.1002/bit.28550
• Peng, J., et al. (2021). Tumor microenvironment responsive pepper mild mottle virus-based nanotubes for targeted delivery and controlled release of paclitaxel. Frontiers in Bioengineering and Biotechnology, 9, 763661. https://doi.org/10.3389/fbioe.2021.763661
• Daniell, H., Kulchar, R. J., Herzog, R. W., Kulis, M., & Leong, K. W. (2023). Plant cell-based drug delivery enhances affordability of biologics. Nature Biotechnology, 41(9), 1186–1187. https://doi.org/10.1038/s41587-023-01899-1
• Devi, N., Singh, P., Sharma, R., Kumar, M., Pandey, S. K., Sharma, R. K., & Wangoo, N. (2022). A lysine-rich cell penetrating peptide engineered multifunctional gold nanoparticle-based drug delivery system with enhanced cellular penetration and stability. Journal of Materials Science, 57(35), 16842–16857. https://doi.org/10.1007/s10853-022-07681-z
• Peng, J., Yin, Y., Liang, H., Lu, Y., Zheng, H., Wu, G., Rao, S., Chen, J., Yan, F., & Hu, J. (2021). Tumor microenvironment responsive pepper mild mottle virus-based nanotubes for targeted delivery and controlled release of paclitaxel. Frontiers in Bioengineering and Biotechnology, 9, 763661. https://doi.org/10.3389/fbioe.2021.763661
• Pawar, P., Anumalla, S., & Sharma, S. (2023). Role of carbon nanotubes (CNTs) in transgenic plant development. Biotechnology and Bioengineering, 120(12), 3493–3500. https://doi.org/10.1002/bit.28550
• Dżaman, K., & Czerwaty, K. (2023). Extracellular vesicle-based drug delivery systems for head and neck squamous cell carcinoma: A systematic review. Pharmaceutics, 15(5). https://doi.org/10.3390/pharmaceutics15051327
• Kazi, M., Alanazi, Y., Kumar, A., Shahba, A. A.-W., Rizwan Ahamad, S., & Alghamdi, K. M. (2023). Oral bioactive self-nanoemulsifying drug delivery systems of remdesivir and baricitinib: A paradigmatic case of drug repositioning for cancer management. Molecules (Basel, Switzerland), 28(5). https://doi.org/10.3390/molecules28052237
• Florian, P. E., Icriverzi, M., Ninciuleanu, C. M., Alexandrescu, E., Trica, B., Preda, S., Ianchis, R., & Roseanu, A. (2020). Salecan-clay based polymer nanocomposites for chemotherapeutic drug delivery systems; Characterization and in vitro biocompatibility studies. Materials, 13(23), 5389. https://doi.org/10.3390/ma13235389
• Khoshfekr Rudsari, H., Zoofaghari, M., Veletic, M., Bergsland, J., & Balasingham, I. (2023). The end-to-end molecular communication model of extracellular vesicle-based drug delivery. IEEE Transactions on Nanobioscience, 22(3), 498–510. https://doi.org/10.1109/TNB.2022.3206908
• Buchke, S., et al. (2022). Mitochondria-targeted, nanoparticle-based drug-delivery systems: Therapeutics for mitochondrial disorders. Life (Basel, Switzerland), 12(5), 657. https://doi.org/10.3390/life12050657
• Chen, Z., et al. (2022). Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 12(8), 3719–3746. https://doi.org/10.7150/thno.72594
• Daniell, H., et al. (2023). Plant cell-based drug delivery enhances affordability of biologics. Nature Biotechnology, 41(9), 1186–1187. https://doi.org/10.1038/s41587-023-01899-1
• Li, Y.-J., et al. (2021). From blood to brain: blood cell-based biomimetic drug delivery systems. Drug Delivery, 28(1), 1214–1225. https://doi.org/10.1080/10717544.2021.1937384
• Loch-Neckel, G., et al. (2022). Challenges in the development of drug delivery systems based on small extracellular vesicles for therapy of brain diseases. Frontiers in Pharmacology, 13, 839790. https://doi.org/10.3389/fphar.2022.839790
• Man, F., et al. (2020). Techniques and applications of animal- and plant-derived exosome-based drug delivery system. Journal of Biomedical Nanotechnology, 16(11), 1543–1569. https://doi.org/10.1166/jbn.2020.2993
• Meng, W., et al. (2020). Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Delivery, 27(1), 585–598. https://doi.org/10.1080/10717544.2020.1748758
• Mozafari, N., et al. (2023). Knowledge gaps in generating cell-based drug delivery systems and a possible meeting with artificial intelligence. Molecular Pharmaceutics, 20(8), 3757–3778. https://doi.org/10.1021/acs.molpharmaceut.3c00162
• Buchke, S., et al. (2022). Mitochondria-targeted, nanoparticle-based drug-delivery systems: Therapeutics for mitochondrial disorders. Life (Basel, Switzerland), 12(5), 657. https://doi.org/10.3390/life12050657
• Chen, Z., et al. (2022). Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 12(8), 3719–3746. https://doi.org/10.7150/thno.72594
• Daniell, H., et al. (2023). Plant cell-based drug delivery enhances affordability of biologics. Nature Biotechnology, 41(9), 1186–1187. https://doi.org/10.1038/s41587-023-01899-1
• Loch-Neckel, G., et al. (2022). Challenges in the development of drug delivery systems based on small extracellular vesicles for therapy of brain diseases. Frontiers in Pharmacology, 13, 839790. https://doi.org/10.3389/fphar.2022.839790
• Meng, W., et al. (2020). Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Delivery, 27(1), 585–598. https://doi.org/10.1080/10717544.2020.1748758

Related Articles